MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$189,407K
Proceeds from exercise of
common stock options
$1,339K
Net cash provided by
financing activities
$190,746K
Net increase
(decrease) in cash and cash...
$35,526K
Canceled cashflow
$155,220K
Maturities of marketable
securities
$16,982K
Stock-based compensation
$2,650K
Accounts payable
$2,206K
Loss from equity
method investment
-$599K
Accrued and other
liabilities
$499K
Operating lease
right-of-use asset
-$88K
Depreciation and
amortization
$29K
Net cash (used in)
provided by investing...
-$144,846K
Net cash used in
operating activities
-$10,374K
Canceled cashflow
$16,982K
Canceled cashflow
$6,071K
Purchases of marketable
securities
$161,737K
Net loss
-$13,692K
Purchases of property and
equipment
$91K
Prepaid and other
current assets
$1,762K
Other assets
$865K
Operating lease liability
-$103K
Accretion related to
marketable securities
$17K
Accounts receivable
$6K
Back
Back
Cash Flow
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)
source: myfinsight.com